safety and activity of ceralasertib in the treatment of mds
Published 2 years ago • 289 plays • Length 3:38Download video MP4
Download video MP3
Similar videos
-
3:08
the treatment protocol for higher risk mds
-
9:38
imetelstat provides durable transfusion independence in lower risk mds group
-
2:17
what are the risk factors for mds?
-
39:28
esc guidelines, clinical assessment for cardiac pacing
-
17:40
1. prevention of ie (english version)
-
14:56
risk control measures in medical device software
-
29:02
ensuring patient safety and image quality the role of the fda
-
14:32
esc guidelines: specific cvds & mutlimorbidity (english version)
-
6:04
what is functional safety?
-
0:58
what is the effect of taking risks ?
-
13:30
medical device regulations and patient safety: comprehensive global policy.
-
3:22
vaccine safety in the immunocompromised
-
39:43
mechanisms of transfusion overuse: aryeh shander, md, fccm, fccp
-
45:29
mighty infection prevention above and beyond - faye mirfakhraee, rn, ms, cic, chcc
-
55:30
mds treatment - side effect management & ask a hematologist
-
2:17
medmarc risk management: fda inspections
-
6:29
hatch d1 - evaluating medicare data to evaluate paclitaxel-coated device safety - dr. secemsky